| Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
|---|
| Dicloxacillin | hsa00500 | Starch and sucrose metabolism | 1.33E-03 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | | Dicloxacillin | hsa00524 | Neomycin, kanamycin and gentamicin biosynthesis | 2.03E-02 | 1 | P35557 | GCK | More | | | Dicloxacillin | hsa00730 | Thiamine metabolism | 3.82E-05 | 3 | Q9Y6K8, P05186, P24666 | AK5, ALPL, ACP1 | More | | | Dicloxacillin | hsa00740 | Riboflavin metabolism | 4.03E-02 | 1 | P24666 | ACP1 | More | | | Dicloxacillin | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | | | Dicloxacillin | hsa03060 | Protein export | 1.90E-02 | 2 | Q15070, O76094 | OXA1L, SRP72 | More | | | Dicloxacillin | hsa04064 | NF-kappa B signaling pathway | 2.45E-03 | 10 | P10415, O00463, P14778, P01375, Q04759, Q13077, Q16548, Q8WV28, P24522, P09341 | BCL2, TRAF5, IL1R1, TNF, PRKCQ, TRAF1, BCL2A1, BLNK, GADD45A, CXCL1 | More | | | Dicloxacillin | hsa04071 | Sphingolipid signaling pathway | 2.06E-02 | 7 | Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415, Q9UQC2 | EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2, GAB2 | More | | | Dicloxacillin | hsa04080 | Neuroactive ligand-receptor interaction | 2.54E-02 | 7 | P08311, Q15722, Q9H228, P21462, P21730, Q16581, P35318 | CTSG, LTB4R, EDG8, FPR1, C5AR1, C3AR1, ADM | More | | | Dicloxacillin | hsa04340 | Hedgehog signaling pathway | 1.43E-02 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | | | Dicloxacillin | hsa04613 | Neutrophil extracellular trap formation | 1.37E-02 | 12 | O60603, P05164, P08246, Q9UM07, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | | Dicloxacillin | hsa04621 | NOD-like receptor signaling pathway | 2.64E-02 | 10 | Q16539, Q14643, P10599, Q9H1Y0, P43490, O00463, P10415, P01375, P09341, P12838 | MAPK14, ITPR1, TXN, ATG5, PBEF1, TRAF5, BCL2, TNF, CXCL1, DEFA4 | More | | | Dicloxacillin | hsa04650 | Natural killer cell mediated cytotoxicity | 2.95E-02 | 7 | P06239, P20963, Q13241, P26718, O14931, P26717, P26715 | LCK, CD247, KLRD1, KLRK1, NCR3, KLRC2, KLRC1 | More | | | Dicloxacillin | hsa04657 | IL-17 signaling pathway | 1.62E-03 | 7 | O00463, Q16539, P49841, P09341, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF | More | | | Dicloxacillin | hsa04658 | Th1 and Th2 cell differentiation | 5.14E-05 | 12 | Q04759, P07766, P20963, P09693, Q16539, P06239, Q14765, P42226, P23771, Q9UL17, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, LCK, STAT4, STAT6, GATA3, TBX21, HLA-DOB, RUNX3 | More | | | Dicloxacillin | hsa04659 | Th17 cell differentiation | 3.18E-02 | 8 | Q04759, Q16539, P42226, P13765, Q9UL17, P23771, P09693, P20963 | PRKCQ, MAPK14, STAT6, HLA-DOB, TBX21, GATA3, CD3G, CD247 | More | | | Dicloxacillin | hsa04660 | T cell receptor signaling pathway | 3.58E-04 | 12 | P01375, Q04759, O95267, Q08881, P07766, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, PRKCQ, RASGRP1, ITK, CD3E, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | | Dicloxacillin | hsa04950 | Maturity onset diabetes of the young | 2.03E-02 | 1 | P35557 | GCK | More | | | Dicloxacillin | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.45E-02 | 4 | Q16539, P09341, P25024, P25025 | MAPK14, CXCL1, CXCR1, CXCR2 | More | | | Dicloxacillin | hsa05140 | Leishmaniasis | 2.69E-02 | 5 | O75015, P13765, O60603, P49006, Q16539 | FCGR3B, HLA-DOB, TLR2, MARCKSL1, MAPK14 | More | | | Dicloxacillin | hsa05146 | Amoebiasis | 4.55E-02 | 5 | P09341, P14778, P27930, O60603, P05089 | CXCL1, IL1R1, IL1R2, TLR2, ARG1 | More | | | Dicloxacillin | hsa05150 | Staphylococcus aureus infection | 4.37E-02 | 6 | P21730, P21462, O75015, P13765, Q16581, P12838 | C5AR1, FPR1, FCGR3B, HLA-DOB, C3AR1, DEFA4 | More | | | Dicloxacillin | hsa05163 | Human cytomegalovirus infection | 3.64E-02 | 7 | Q14643, P49841, P14778, P25025, Q16539, P04637, O00463 | ITPR1, GSK3B, IL1R1, CXCR2, MAPK14, TP53, TRAF5 | More | | | Dicloxacillin | hsa05169 | Epstein-Barr virus infection | 4.32E-02 | 11 | P13765, O00463, P16070, P10415, Q16539, P24522, Q8WV28, P01375, O60603, P09693, P20963 | HLA-DOB, TRAF5, CD44, BCL2, MAPK14, GADD45A, BLNK, TNF, TLR2, CD3G, CD247 | More | | | Dicloxacillin | hsa05202 | Transcriptional misregulation in cancer | 8.07E-04 | 14 | Q15532, P14780, P27930, Q16548, Q13077, Q15652, O15550, P35226, P05164, P12838, P08246, Q9C0K0, P41182, P24522 | SS18, MMP9, IL1R2, BCL2A1, TRAF1, JMJD1C, UTX, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, GADD45A | More | | | Dicloxacillin | hsa05217 | Basal cell carcinoma | 1.43E-02 | 4 | Q13635, P49841, Q9UJU2, P24522 | PTCH1, GSK3B, LEF1, GADD45A | More | | | Dicloxacillin | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | | | Dicloxacillin | hsa05224 | Breast cancer | 4.75E-02 | 4 | P49841, Q92837, P04637, P24522 | GSK3B, FRAT1, TP53, GADD45A | More | | | Dicloxacillin | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4.55E-02 | 5 | O95267, P09693, O60603, Q16539, P01730 | RASGRP1, CD3G, TLR2, MAPK14, CD4 | More | | | Dicloxacillin | hsa05321 | Inflammatory bowel disease | 7.62E-04 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P42226, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, STAT6, GATA3 | More | | | Dicloxacillin | hsa05418 | Fluid shear stress and atherosclerosis | 2.62E-02 | 6 | Q16539, P10599, P14780, P04637, P14778, P27930 | MAPK14, TXN, MMP9, TP53, IL1R1, IL1R2 | More | |
|
